Trial Profile
A Phase II Study of Risk-adapted Donor Lymphocyte Infusion and Azacitidine for the Prevention of Hematologic Malignancy Relapse Following Allogeneic Stem Cell Transplantation
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 13 Oct 2020
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Juvenile myelomonocytic leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions; Therapeutic Use
- 09 Oct 2020 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Apr 2020.
- 01 Apr 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Mar 2020.